Unity Biotechnology Stock Forecast, Price & News

-0.25 (-5.31 %)
(As of 06/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume394,282 shs
Average Volume631,795 shs
Market Capitalization$244.65 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology logo

About Unity Biotechnology

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.39 out of 5 stars

Medical Sector

746th out of 2,100 stocks

Analyst Opinion: 3.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

Is Unity Biotechnology a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Unity Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UBX, but not buy additional shares or sell existing shares.
View analyst ratings for Unity Biotechnology
or view top-rated stocks.

What stocks does MarketBeat like better than Unity Biotechnology?

Wall Street analysts have given Unity Biotechnology a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Unity Biotechnology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Unity Biotechnology

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) issued its quarterly earnings data on Wednesday, May, 12th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.09.
View Unity Biotechnology's earnings history

How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UBX shares have decreased by 17.3% and is now trading at $4.46.
View which stocks have been most impacted by COVID-19

What price target have analysts set for UBX?

6 brokerages have issued 1 year price objectives for Unity Biotechnology's shares. Their forecasts range from $4.00 to $12.00. On average, they expect Unity Biotechnology's share price to reach $6.00 in the next year. This suggests a possible upside of 34.5% from the stock's current price.
View analysts' price targets for Unity Biotechnology
or view top-rated stocks among Wall Street analysts.

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Anirvan Ghosh, CEO & Director (Age 57, Pay $758.57k)
  • Ms. Lynne Marie Sullivan, CFO & Head of Corp. Devel. (Age 55, Pay $471.36k)
  • Dr. Jamie Dananberg, Chief Medical Officer (Age 63, Pay $625.59k)
  • Dr. Nathaniel E. David, Co-Founder & Exec. Director (Age 53)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder
  • Mr. Daohong Zhou M.D., Founder
  • Mr. Nathan Guz Ph.D., VP of Operations
  • Mr. Alexander Azoy, VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer (Age 45)
  • Dr. Przemyslaw Sapieha Ph.D., Chief Scientific Advisor

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering (IPO) on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.19%), Geode Capital Management LLC (1.01%), Northern Trust Corp (0.67%), Russell Investments Group Ltd. (0.34%), Morgan Stanley (0.31%) and Nuveen Asset Management LLC (0.25%).
View institutional ownership trends for Unity Biotechnology

Which major investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Russell Investments Group Ltd., Goldman Sachs Group Inc., BlackRock Inc., Saturna Capital CORP, Northern Trust Corp, Squarepoint Ops LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Unity Biotechnology
or view top insider-selling stocks.

Which major investors are buying Unity Biotechnology stock?

UBX stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Dimensional Fund Advisors LP, Ballentine Partners LLC, Cubist Systematic Strategies LLC, Nuveen Asset Management LLC, JPMorgan Chase & Co., Barclays PLC, and Alliancebernstein L.P..
View insider buying and selling activity for Unity Biotechnology
or or view top insider-buying stocks.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $4.46.

How much money does Unity Biotechnology make?

Unity Biotechnology has a market capitalization of $244.65 million.

How many employees does Unity Biotechnology have?

Unity Biotechnology employs 63 workers across the globe.

What is Unity Biotechnology's official website?

The official website for Unity Biotechnology is

How can I contact Unity Biotechnology?

The company can be reached via phone at 650 416 1192.

This page was last updated on 6/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.